GlassScriptPhysician profile
Carlos Galindo
NPI 1376739581
$2,985.57
in general payments reported to CMS, 2019-2025
24 companies · $974 in 2025
The $974 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $178 · 2021: $48.81 · 2022: $344 · 2023: $509 · 2024: $722 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $452.66 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $338.44 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $222.10 | 2021-2025 | |
| Lilly USA, LLC | $167.64 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.60 | 2023-2025 | Jardiance |
| Pfizer INC. | $109.34 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $98.58 | 2019-2025 | |
| Dexcom, INC. | $98.19 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $97.68 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $78.35 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $74.13 | 2025 | Daybue |
| Exact Sciences Corporation | $73.97 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $59.43 | 2020-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $47.94 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.97 | 2019-2020 | |
| Dynavax Technologies Corporation | $42.92 | 2022-2024 | Heplisav-B |
| Medtronic, INC. | $41.48 | 2023-2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $36.82 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.64 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.34 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.72 | 2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2024 | Rexulti |
| Neuronetics, INC. | $16.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Galindo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.